highly significantp ≤0.001
The fact that the present study provided highly significant beneficial response (p ≤0.001) with more than 50% reduction in severity scores for more than 80% of subjects in the Asafin group demonstrates the efficacy of Asafin over the placebo group with only less than 13% improvement in the symptoms score.